Doberstein et al. evaluated the therapeutic efficacy of anti-L1CAM treatment on the syngeneic tumor models RET (melanoma) and Panc02 (pancreatic adenocarcinoma), both genetically manipulated to express L1CAM [123]. Here, L1CAM is linked to melanoma.